PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCyclophosphamide
Cyclophosphamide
Cyclophosphamide, Cytoxan (cyclophosphamide) is a small molecule pharmaceutical. Cyclophosphamide was first approved as Cytoxan on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, BCR-ABL positive chronic myelogenous leukemia, breast neoplasms, burkitt lymphoma, and endometrial neoplasms amongst others in the USA.
Download report
Favorite
Drugs Approved for Childhood Cancers
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
nervous system diseasesD009422
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
Show 4 more
Trade Name
FDA
EMA
Cyclophosphamide, Cytoxan (discontinued: Cyclophosphamide, Cytoxan (lyophilized), Neosar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cyclophosphamide
Tradename
Company
Number
Date
Products
CYTOXANBaxterN-012141 RX1982-01-01
2 products, RLD
CYCLOPHOSPHAMIDEBaxterN-217651 RX2023-06-28
2 products, RLD, RS
CYCLOPHOSPHAMIDEDr Reddys LaboratoriesN-212501 RX2020-07-30
3 products, RLD, RS
CYCLOPHOSPHAMIDEDr Reddys LaboratoriesN-210852 RX2023-06-07
3 products, RLD, RS
CYCLOPHOSPHAMIDEEugia Pharma SpecialtiesN-210735 RX2021-08-25
3 products, RLD, RS
CYCLOPHOSPHAMIDEHikma PharmaceuticalsN-203856 RX2013-09-16
2 products, RLD, RS
CYCLOPHOSPHAMIDESandozN-217150 RX2023-09-12
3 products, RLD, RS
Show 4 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cyclophosphamideNew Drug Application2050-01-04
frindovyxNew Drug Application2025-01-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myeloid leukemia acute—D015470C92.0
breast neoplasmsEFO_0003869D001943C50
ovarian neoplasmsEFO_0003893D010051C56
endometrial neoplasmsEFO_0004230D016889—
nephrotic syndromeEFO_0004255D009404N04
multiple sclerosisEFO_0003885D009103G35
lung neoplasms—D008175C34.90
multiple myeloma—D009101C90.0
neuroblastomaEFO_0000621D009447—
precursor cell lymphoblastic leukemia-lymphoma—D054198C91.0
Show 18 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Cyclophosphamide, Cyclophosphamide, Ingenus Pharms Llc
109939522036-02-15DP
Cyclophosphamide, Cyclophosphamide, Eugia Pharma Speclts
96623422035-06-26DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01A: Alkylating agents
— L01AA: Nitrogen mustard analogues
— L01AA01: Cyclophosphamide
HCPCS
Code
Description
C9087
Injection, cyclophosphamide, (auromedics), 10 mg
J8530
Cyclophosphamide; oral, 25 mg
J9070
Cyclophosphamide, 100 mg
Clinical
Clinical Trials
4965 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.940076021122731287
LeukemiaD007938—C953545681491960987
Breast neoplasmsD001943EFO_0003869C501424642352589872
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0191282791829510
Non-hodgkin lymphomaD008228—C85.919728165730493
Lymphoid leukemiaD007945—C91184273761721488
Multiple myelomaD009101—C90.014825550628435
B-cell lymphomaD016393——19022454618416
Plasma cell neoplasmsD054219——12320348620359
Large b-cell lymphoma diffuseD016403—C83.311220761515348
Show 84 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8025818621—28418
Myeloid leukemia acuteD015470—C92.010917341—16292
Myeloid leukemiaD007951—C929916936—17277
Hematologic neoplasmsD019337——7110411—17171
MelanomaD008545——86883—3147
CarcinomaD002277—C80.086647—5132
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—259312—7122
Ovarian neoplasmsD010051EFO_0003893C5676576—4119
SarcomaD012509——485619—8117
Myeloproliferative disordersD009196—D47.128794—11113
Show 195 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C254536——366
Liver neoplasmsD008113EFO_1001513C22.03219——342
Stomach neoplasmsD013274EFO_0003897C163817——140
Prostatic neoplasmsD011471—C612910——135
Hepatocellular carcinomaD006528—C22.02418——333
Uterine cervical neoplasmsD002583——2412———28
Skin neoplasmsD012878EFO_0004198C441120———26
Prolymphocytic leukemiaD015463——718——124
MesotheliomaD008654—C451913———22
Esophageal neoplasmsD004938—C15209———21
Show 264 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Female genital neoplasmsD005833——6———17
Adrenocortical carcinomaD018268——3————3
Antiphospholipid syndromeD016736EFO_0002689D68.611———23
Nervous system diseasesD009422—G00-G993————3
PregnancyD011247EFO_0002950Z33.11———12
Juvenile arthritisD001171EFO_1002007M081———12
AnalgesiaD000698——2————2
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A2————2
Immunoglobulin g4-related diseaseD000077733—D89.841———12
Bile duct neoplasmsD001650——2————2
Show 31 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemoglobin sc diseaseD006450EFO_1001797D57.2————22
Type 1 hyper-igm immunodeficiency syndromeD053307——————22
Hyper-igm immunodeficiency syndromeD053306Orphanet_101088D80.5————22
Cytomegalovirus infectionsD003586EFO_0001062B25————22
Hemoglobin c diseaseD006445—D58.2————11
Taste disordersD013651——————11
DysgeusiaD004408—R43.2————11
AgeusiaD000370EFO_1001758—————11
AtaxiaD001259—R27.0————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
Show 52 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCyclophosphamide
INNcyclophosphamide
Description
Cyclophosphamide is a phosphorodiamide that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by two 2-chloroethyl groups at the amino nitrogen atom. It has a role as a carcinogenic agent, an alkylating agent, an immunosuppressive agent, an antineoplastic agent, an antirheumatic drug, an environmental contaminant, a xenobiotic and a drug allergen. It is a phosphorodiamide, a nitrogen mustard and an organochlorine compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O.O=P1(N(CCCl)CCCl)NCCCO1
Identifiers
PDB—
CAS-ID6055-19-2
RxCUI—
ChEMBL IDCHEMBL1200796
ChEBI ID4026
PubChem CID2907
DrugBankDB00531
UNII ID6UXW23996M (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cyclophosphamide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 41,439 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
150,346 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use